Shots: Skyhawk to receive upfront, milestones & royalties on sales and will discover & preclinically develop targeted therapies utilizing its SkySTAR technology. Takeda to get an exclusive WW license to […]readmore
Tags : Takeda
Shots: The submission is based on METEOR, CABOSUN and Takeda’s bridging study. METEOR & CABOSUN studies result assessing Cabometyx vs everolimus & sunitinib in patients with RCC + prior treated […]readmore
Shots: Emendo to receive convertible notes from Takeda Ventures, will convert it into SeriesB funding utilizing it to advance its gene editing discovery platform & biotherapies into clinical trials. Takeda […]readmore
Shots: StrideBio to receive $30M upfront & near term pre-clinical milestones, $680M as development and commercial milestones & royalties on global sales of products. Takeda to get rights for clinical […]readmore
Biotech
Pharma
Takeda Collaborates with LegoChem Biosciences (LCB) to Develop Antibody-Drug Conjugates
Shots: LCB to receive $7.25M upfront, $404M as regulatory & commercial milestones and royalties on sales of ADCs product. Takeda licenses rights for LCB’s ConjuAll technology including linker and conjugation […]readmore
Shots: Lupus Therapeutics (subsidiary of Lupus Research Alliance) collaborates with Takeda to evaluate TAK-079 (NCT03724916) in P-I clinical study assessing TAK-079 vs PBO in 24 patients with moderate to severe […]readmore
Shots: The approval is based on P-III ECHELON-1 study result assessing Adcetris + AVD (adriamycin, vinblastine and dacarbazine) vs ABVD (adriamycin, bleomycin, vinblastine and dacarbazine) in patients with previously untreated […]readmore
Shots: The P-III TIDES study contains three parts assessing TAK-003 (0.5ml, SC) vs PBO in patients for the prevention of dengue fever of any severity and due to any of […]readmore
Shots: Enterome to get $50M upfront plus $640M as milestones payments and future equity investment commitment from Takeda. The companies will jointly co-develop EB8018 and if approved, the product will […]readmore
Shots: Takeda will provide upfront of $30M and to pay royalties on commercialization. CD38-Targeted ETBs’ development cost will be shared equally between both the parties Molecular Templates will receive development, […]readmore